-
Mashup Score: 0
In a final overall survival analysis of the phase 3 PROpel study, abiraterone actetate/olaparib demonstrates a sustained trend toward overall survival for metastatic castration-resistant prostate cancer vs standard-of-care abiraterone.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma - PubMed - 1 year(s) ago
We identified specific gene isoforms in both the canonical and non-canonical HIF pathways associated with metastatic RCC survival. EGLN3 and BNIP3 showed significant interaction with treatment arm and may be predictive of treatment response. We have identified genes for future prospective investigat …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Much deserved and huge congrats to new uro chair @CedarsSinai @HyungLKim still has time to run our biweekly #GU onc multi-D TB and highly collaborative - check out our recent @UrolOncol work on #HIF gene isoforms as novel biomarkers and targets in #ccRCC https://t.co/bBtkODH6n4 https://t.co/NkvemsesWJ https://t.co/Cv65ygbXkE
-
-
Mashup Score: 0HOME - New York GU™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies - 1 year(s) ago
New York GU™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join PER® for the 16th Annual NYGU™ conference from March 10-11 with #GU experts. Hear about the latest trials from clinical trials of novel therapeutic strategies and much more. Use code NYGU35S for 35% off registration: https://t.co/Qbi4wK1w1l #prostate #genitourinary https://t.co/yW67dpPrx8
-
-
Mashup Score: 0HOME - New York GU™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies - 1 year(s) ago
New York GU™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join us for the 16th Annual NYGU™ conference from March 10-11 with #GU experts. Hear about the latest trials from clinical trials of novel therapeutic strategies and much more. Use code NYGU35S for 35% off registration: https://t.co/IU35nB5d48 #pcsm #cme https://t.co/OjE99eNuCz
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 2 year(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
It was great to speak with Michael Strijbos who discussed what to watch out for in #GUsm at #ESMO22 We’ll be updating https://t.co/ys1d8pDAKO over the next few days so make sure to keep your eyes peeled 👀 @myESMO #GU https://t.co/oYI5CcY3I7
-
-
Mashup Score: 0The Cancer News Daily - 2 year(s) ago
The latest in cancer medicine and translational research by Wafik El-Deiry MDPhD
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Cancer News Daily! https://t.co/Vbzguas4Ql Thanks to @FightCRC @MDAndersonNews @OncLive #esmo22 #gu
-
-
Mashup Score: 14ESMO Congress 2022: Registration - 2 year(s) ago
Individual registration is still open
Source: www.esmo.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
As #ESMO22 is approaching, here are my list of Top 15 #GU Oncology presentations, just based on "Titles"... This list may ultimately change after abstracts release https://t.co/pJCTDQnzb4 @myESMO @KKronig @FedefedeFri https://t.co/xLfYPrEENn
-
-
Mashup Score: 2Immunotherapy in synchronous MSI-H rectal adenocarcinoma and upper tract urothelial carcinoma: a case report - 2 year(s) ago
Immunotherapy in synchronous MSI-H rectal adenocarcinoma and upper tract urothelial carcinoma: a case report
Source: jgo.amegroups.comCategories: Latest Headlines, Oncologists1Tweet-
#GI #GU onc case @MayCho_MD learning points 1) 4 yrs ago but c/w potential lack of response to neoadj chemo and chemoRT in #MSI-H #rectal cancer, 2) role of neoadj and adj IO in this #dMMR space, 3) #IO as a unifying tx for synchronous #Lynch cancers? https://t.co/hPZwfzDSLU https://t.co/Z8s3aHEXjE
-
-
Mashup Score: 1
Submit an Article | Journal of Immunotherapy and Precision Oncology Submit an Article Instructions for Authors Before submitting your article, please read the Instructions for Authors (updated March 2022) to understand the requirements for preparing and submitting a manuscript to the Journal. Please note that manuscripts not conforming to the Journal’s instructions may be returned…
Source: meridian.allenpress.comCategories: Latest Headlines, Oncologists1Tweet-
RT @JIPOEditors: #JIPO is seeking manuscripts on #genitourinary oncology, to be edited by Dr Mehmet Bilen. https://t.co/8hAnQsY1lI #GU #C…
-
-
Mashup Score: 2Podcast: Key Posters on Advances in GU Cancers at ASCO22 - 2 year(s) ago
Guest host Dr. Neeraj Agarwal, of the University of Utah Huntsman Cancer Institute and the ASCO Daily News editor-in-chief, discusses key therapeutic advances in mRCC and mUC, as well as new research that proposes periodic scans to monitor patients with mCSPC for disease progression, with Dr. Jeanny-Aragon-Ching of the Inova Schar Cancer Institute.
Source: ASCO Daily NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
In this podcast, we discuss key #ASCO22 #GU posters e.g. defining platinum ineligibility in UC, rPFS/PSA progression in mCSPC, predicting PSA recurrence with PSMAPET, new data on belzutifan, microbiome/IOs in mRCC @oncoalert @ASCO #ASCODailyNews Podcast👉https://t.co/utrPVFnrao https://t.co/2bAe6OedEs https://t.co/uQ638FfzH5
-
Abiraterone acetate plus olaparib improved efficacy vs SOC abiraterone in metastatic castration-resistant prostate cancer. #pcsm #GU | @ASCO https://t.co/blnAcAQ1Cx